SK Biopharmaceuticals
 | This article appears to have been generated by a large language model (such as ChatGPT) without having been rigorously scrutinized for verifiability, neutrality, original research, and copyright compliance. It may include misleading or inaccurate claims and fake references that sound plausible. (March 2025) (Learn how and when to remove this template message) |
SK Biopharmaceuticals
| Public | |
| ISIN | 🆔 |
| Industry | Pharmaceutical |
| Founded 📆 | 2011 |
| Founder 👔 | |
Area served 🗺️ | |
| Members | |
Number of employees | |
| Parent | SK Group |
| 🌐 Website | www |
| 📇 Address | |
| 📞 telephone | |
SK Biopharmaceuticals Co., Ltd. is a South Korean biopharmaceutical company specializing in the research, development, and commercialization of treatments for central nervous system (CNS) disorders and oncology. It operates as a subsidiary of the SK Group and is headquartered in Bundang, Seongnam, Gyeonggi Province, South Korea.
History
SK Biopharmaceuticals originated as a division of SK Chemicals in 1993 and became an independent company in 2011. The company focuses on CNS therapeutics and gained industry recognition after developing cenobamate (XCOPRI®), an anti-epileptic drug that received approval from the U.S. Food and Drug Administration (FDA) in November 2019.[1]
In July 2020, SK Biopharmaceuticals was listed on the Korea Exchange (KRX).[2]
Research and Development
SK Biopharmaceuticals engages in research and development across multiple therapeutic areas.
CNS Therapeutics
Cenobamate (XCOPRI®/ONTOZRY®): Approved for treating partial-onset seizures in adults. By March 2024, over 100,000 patients worldwide had been treated with cenobamate.[3]
Solriamfetol (SUNOSI®): A treatment for excessive daytime sleepiness in patients with narcolepsy and obstructive sleep apnea. Developed by SK Biopharmaceuticals and later out-licensed.[4]
Oncology and Radiopharmaceuticals
Radiopharmaceutical Therapy (RPT): The company has secured supply agreements for Actinium-225 (Ac-225) with TerraPower and PanTera for use in radiopharmaceutical cancer treatments.[5] Targeted Protein Degradation (TPD): Developing oncology treatments through SK Life Science Labs, its U.S. subsidiary.[6]
Recent Developments
In April 2024, the FDA approved new administration methods for XCOPRI®, allowing tablets to be crushed and taken orally or via a nasogastric tube for patients with partial-onset seizures.[7]
References
- ↑ "FDA approves new treatment for adults with partial-onset seizures". U.S. Food and Drug Administration. November 21, 2019. Retrieved March 7, 2025.
- ↑ "SK Biopharmaceuticals makes successful market debut on Korea Exchange". The Korea Times. July 2, 2020. Retrieved March 7, 2025.
- ↑ "Angelini Pharma and SK Biopharmaceuticals announce treatment of over 100,000 patients globally with cenobamate". PharmaTimes. March 11, 2024. Retrieved March 7, 2025.
- ↑ "SK Life Science: A History of Discovery". SK Life Science. Retrieved March 7, 2025.
- ↑ "SK Biopharmaceuticals secures Actinium-225 for next-gen radiopharmaceuticals". Business Korea. August 28, 2023. Retrieved March 7, 2025.
- ↑ "SK Life Science Labs: About Us". SK Life Science Labs. Retrieved March 7, 2025.
- ↑ "FDA approves alternate administration for SK Biopharmaceuticals' XCOPRI". PR Newswire. April 2024. Retrieved March 7, 2025.
Categories
This article "SK Biopharmaceuticals" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:SK Biopharmaceuticals. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
